myDC/pDC in Stage III Melanoma Patients

• Status: Completed
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an interventional study to test the immunogenicity of combined adjuvant myDC and pDC vaccination versus adjuvant myDC or pDC vaccination alone in stage III melanoma patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Treatments: Vaccines

Criteria

Inclusion Criteria:

• stage III melanoma

• WHO performance status 0-1

• radical lymph node dissection is schedule or performed within 12 weeks prior to start of study treatment

Exclusion Criteria:

• irresectable disease

• any concurrent adjuvant therapy

• concomitant use of oral immunosuppressive drugs

• autoimmune diseases